HCR 561 Discussion 3: Quality by Design
HCR 561 Discussion 3: Quality by Design
Using Quality by Design (QbD) means taking a planned and systematic approach to ensuring the quality of pharmaceutical products and clinical trials. The ICH E8(R1) guidance emphasizes that using Quality by Design helps plan clinical trials in a way that identifies important factors affecting participant safety, data accuracy, and trial outcomes early on. This approach reduces the need to depend only on final quality checks (Whitehead et al., 2023).
“Quality must be built in” means that you should design quality from the start, not just add it in later. This approach is also supported by the FDA’s document, “Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring,” released in 2013. It outlines the need for planning and careful oversight using risk assessment to make sure trials are performed properly and deliver useful results from the beginning (Whitehead et al., 2023).
To improve the standard of a clinical trial, certain significant practices should be incorporated:
Clear Objectives and Protocol Design: Clarify what the study is trying to achieve and confirm that the protocol follows scientific and ethical standards. As required by ICH E6(R2) Good Clinical Practice, the protocol should spell out the steps to be taken, the study outcomes, who can take part, and the statistical methods to lessen discrepancies during the study (Bhatt, 2023).
Risk Assessment and Critical Data Identification: Find out early in the process which data and systems end up being critical and what threats they might face. ICH E8(R1) states that “Critical to Quality” (CtQ) factors are important because they ensure good results and everyone remains safe (Whitehead et al., 2023).
Stakeholder Collaboration: It is important to bring experts from various departments (such as clinical operations, data management, and regulatory affairs) into trial planning early to ensure the process will be possible and follow all relevant regulations (Bhatt, 2023).
Continuous Improvement: Monitor the trial process using metrics and indicators to ensure it keeps improving during the trial lifecycle (Ogg, 2005).
References
Bhatt, A. (2023). The revamped Good Clinical Practice E6 (R3) guideline: Profound changes in principles and practice!. Perspectives in Clinical Research, 14(4), 167-171.
Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC
Press.
Whitehead, M., Suprin, M., Mistree, T., Kearns, M. M., Marini, G., Goffe, C., Pillwein, M., & Abdul-Shukkoor, V. (2023). The Renovation of Good Clinical Practice: A framework for key components of ICH E8. Therapeutic Innovation & Regulatory Science, 58(2), 303–310. https://doi.org/10.1007/s43441-023-00561-x
HCR 561 Discussion 3: Quality by Design
